NPM1 and acute myeloid leukemia: Here, in this study, we have further expanded on the utility of ScPGseq to understand the AML development and relapse in a single case of AML, that at presentation had been assigned to the ELN favorable‐risk group based on the presence of NPM1 mutation and the low FLT3‐ITD AR at presentation.